In a game-changing move, Victory Square Technologies Inc.'s portfolio company, Hydreight Technologies Inc., has unveiled a groundbreaking addition to its product offerings. Semaglutide, a cutting-edge medication for type 2 diabetes and weight management, is now accessible through the Hydreight platform.

Background and Context

Victory Square, a venture builder with a focus on early-stage tech companies, has nurtured Hydreight into a trailblazer in the mobile clinical network and medical platform sector. Hydreight's mission revolves around delivering essential healthcare services at the convenience of patients' homes across 50 states in the United States.

Key Highlights and Advantages

• Revolutionizing Weight Management: Semaglutide injections, known for controlling blood sugar and aiding weight loss, have been added to Hydreight's arsenal. This move aligns with the growing global demand for anti-obesity medications, projected by Goldman Sachs to reach $100 billion by 2030.
• Pioneering Patient-Centric Care: Hydreight's proprietary platform, already offering a suite of healthcare services, now provides a comprehensive approach, including lab tests, prescriptions, drug delivery, administration, monitoring, and follow-ups. The integration of Semaglutide marks a shift from preventative medicine to essential healthcare.

Potential Impact and Significance

The addition of Semaglutide positions Hydreight at a pivotal point, tapping into the burgeoning demand for weight management solutions. The global shift towards obesity, as projected by World Obesity Atlas 2023, underscores the significance of Hydreight's move in addressing a critical health concern.

Expert Opinions and Analysis

Shane Madden, CEO of Hydreight, emphasizes the strategic significance, stating, "Adding access to Semaglutide through our platform is the first step in our shift from preventative medicine to essential healthcare, and we are only just getting started." The company's vision aligns with providing continuous care and improving patient outcomes through innovative technology.

Challenges and Considerations

While the demand for weight management solutions is high, Hydreight acknowledges the need for careful and responsible healthcare delivery. The platform's expansion into lab testing and additional blood tests next year indicates a commitment to holistic patient care.

Conclusion

Hydreight's integration of Semaglutide showcases Victory Square's commitment to driving value in its portfolio companies. The move not only addresses a critical health need but also positions Hydreight as a leader in mobile medicine, offering an integrated and patient-centric approach to healthcare delivery.

Victory Square will be hosting an EOY Investor Webinar with CEO Shafin Diamond Tejani on December 28th, 2023, presenting a corporate update, notable portfolio highlights, and insights into the 2024 outlook.

View original release: https://www.globenewswire.com/news-release/2023/12/20/2799177/0/en/Victory-Square-Portfolio-Company-Hydreight-Adds-Semaglutide-to-Product-Offerings.html